Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies

  • Mirko Pinotti
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Raffaella Toso
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Domenico Girelli
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Debora Bindini
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Paolo Ferraresi
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Maria L. Papa
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Roberto Corrocher
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Giovanna Marchetti
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.
  • Francesco Bernardi
    From the Dipartimento di Biochimica e Biologia Molecolare-CIBF, Università di Ferrara, Ferrara, Italy; the Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy; and the Centro Emofilia e Trombosi, Ospedale Nuovo Pellegrini, Naples, Italy.

抄録

<jats:title>Abstract</jats:title><jats:p>Previous studies have established that factor VII gene (F7) polymorphisms (5′F7 and R353Q) contribute about one-third of factor VII (FVII) level variation in plasma. However, F7 genotyping in patients with cardiovascular disease has produced conflicting results. Population and expression studies were used to investigate the role of intron 7 (IVS7 ) polymorphisms, including repeat and sequence variations, in controlling activated FVII (FVIIa) and antigen (FVIIag) levels. Genotype–phenotype studies performed in 438 Italian subjects suggested a positive relation between the IVS7 repeat number and FVII levels. The lowest values were associated with theIVS7 + 7G allele. The screening of 52 patients with mild FVII deficiency showed an 8-fold increase in frequency (8%) of this allele, and among heterozygotes for identical mutations, lower FVII levels were observed in the IVS7 + 7G carriers. This frequent genetic component participates in the phenotypic heterogeneity of FVII deficiency. The evaluation of the individual contribution of polymorphisms was assisted by the expression of each IVS7variant, as a minigene, in eukaryotic cells. The novel quantitative analysis revealed that higher numbers of repeats were associated with higher mRNA expression levels and that the IVS7 + 7Gallele, previously defined as a functionally silent polymorphism, was responsible for the lowest relative mRNA expression. Taken together, these findings indicate that the IVS7 polymorphisms contribute to the plasmatic variance of FVII levels via differential efficiency of mRNA splicing. These studies provide further elements to understand the control of FVII levels, which could be of importance to ensure the hemostatic balance under pathologic conditions.</jats:p>

収録刊行物

  • Blood

    Blood 95 (11), 3423-3428, 2000-06-01

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ